A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
A total of 22 new companies were founded in 2014 by researchers from ETH Zurich. These spin-offs are among the most successful in Switzerland. One of the year's highlights was Covagen, which was acquired for over CHF 200 million. The latest figures also reveal that the university is on the right track with its promotion programmes.
To stay competitive in the global race to develop advanced manufacturing technologies, German industry must define and develop the digital framework for the “Internet of Things,” enabling everything from driverless cars to smart cities and e-health, a top official tells Science|Business
Portugal-based Gulbenkian Foundation will join an established research team, active in 11 African countries, to help fight rampant diseases like malaria and AIDS
Incessant talk of a North-South R&D divide is not baseless but it’s becoming tired. It is time to try and change things says Carlos Zorrinho, Brussels’ quiet revolutionary
The long-gestating Europe-wide patent, due to arrive at the start of 2015, is late. There remains uncertainty over the fees and the strength of the unified patent court, but EPO head Benoît Battistelli says don’t rush to judgement
Researchers at University of Bologna designed the first self-assembling molecular motor capable of converting light energy into work. The study was published in Nature Nanotechnology.
Three out of four Starting grants go to young researchers hosted by Germany, UK, France, the Netherlands, Israel and Spain. There are no grants going to Switzerland
ETH Zurich and the University of Zurich are founding a new translational research centre at the interface of medicine, science and engineering: the Wyss Translational Center Zurich. A USD 120 million donation from Dr. h.c. mult. Hansjörg Wyss to the two Zurich universities is making this possible. Through an interdisciplinary approach, the new centre aims to accelerate the development and application of innovative medical therapies and groundbreaking robotic systems.
For five years, robotics expert and Executive Board member Roland Siegwart has held the post of Vice President Research and Corporate Relations. He is now in the process of handing over this vice presidency to his successor, Detlef Günther, but he will always remain a firm fan of ETH Zurich.
In the race to create world-beating technology companies from scratch, Germany spent most of the past thirty years on the sidelines. But the country’s start-up ecosystem is now flourishing - and foreign investors are taking a second look
ETH Zurich and the Wilhelm Schulthess Foundation are set to expand their research and teaching collaboration. ETH Zurich will establish a new chair to study how physical activity affects human physiology and long-term well-being. The Wilhelm Schulthess Foundation is supporting the creation of the Chair of Physical Activity and Health with 10 million Swiss francs over a 10-year period.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.